Autosomal Dominant Polycystic Kidney
Nephrology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Boehringer IngelheimEmpagliflozin 10 MG
Centessa PharmaceuticalsLixivaptan
BiogenBardoxolone methyl oral capsule
Clinical Trials (3)
Total enrollment: 711 patients across 3 trials
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Start: Jun 2024Est. completion: May 202744 patients
Phase 4Active Not Recruiting
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Start: Oct 2021Est. completion: Aug 2022
Phase 3Terminated
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
Start: May 2019Est. completion: Aug 2023667 patients
Phase 3Terminated
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
1w ago
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Specialty Account Manager, Nephrology- South Houston, Texas
Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space